Sendai, Japan

Yoshiji Matsuda

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Kabushiki Kaisha Kayaku Kosei Bushitsu Kenkyujo, Kabushiki Kaisha Saikin Kagaku Kenkyujo. Active years: 1981.


% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 1981

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Yoshiji Matsuda

Introduction

Yoshiji Matsuda is a notable inventor based in Sendai, Japan. He is recognized for his contributions to the field of medical diagnostics, particularly in cancer detection. His innovative approach has led to the development of a unique immune serum that has significant implications for cancer diagnosis.

Latest Patents

Matsuda holds a patent for an "Immune serum for diagnosis of cancer and preparation thereof." This invention provides a method for preparing a specific immune serum by immunizing IAP in animals other than humans and absorbing the resulting serum with normal human serum. This groundbreaking work has the potential to enhance cancer diagnostic methods significantly.

Career Highlights

Throughout his career, Matsuda has worked with several prominent companies, including Kabushiki Kaisha Kayaku Kosei Bushitsu Kenkyujo and Kabushiki Kaisha Saikin Kagaku Kenkyujo. His experience in these organizations has contributed to his expertise in the field of immunology and cancer research.

Collaborations

Matsuda has collaborated with notable colleagues such as Keiji Tamura and Fumio Kitame. Their joint efforts have further advanced the research and development of innovative medical solutions.

Conclusion

Yoshiji Matsuda's contributions to cancer diagnostics through his patented immune serum exemplify the impact of innovation in medicine. His work continues to inspire advancements in the field and holds promise for future breakthroughs.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…